Cape Girardeau, Missouri news highlights UC clinical trial
Study to test neurostimulation to treat opioid withdrawal, PTSD
KFVS-TV in Cape Girardeau, Missouri highlighted a University of Cincinnati clinical trial testing a wearable neurostimulation device to help patients with opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) stick with medication treatment while finding the right dose.
UC's Joel Sprunger, principal investigator of the trial, said the medication buprenorphine is an effective treatment to help patients with OUD manage symptoms of opioid use disorder withdrawal, but there is an adjustment period of up to three months as each patient finds the right dose to manage their symptoms.
In response to this challenge, the trial will utilize the Sparrow Ascent – a patient-administered wearable device that delivers mild electrical stimulation to the cranial branches of the vagus and trigeminal nerves on and around the ear.
Sprunger said the stimulation “pumps the brakes” on the sympathetic nervous system by enhancing parasympathetic activity, helping to transition someone from fight-or-flight to “rest and digest.”
“By providing people control over that stimulation, we can empower them with a way to turn it on when needed and feel some relief,” said Sprunger, assistant professor of psychiatry and behavioral neuroscience in UC’s College of Medicine. “Their heart rate slows down, breathing slows down and there’s a lot less of a sense of panic and urgency. So that’s the key ingredient that we think will hit both PTSD and opioid withdrawal symptoms at the same time.”
The trial is enrolling patients at the Gibson Center for Behavioral Change in Cape Girardeau.
“It does give the patient some ownership and some control over their treatment,” Ryan Essex, Gibson Center chief operating officer, told KFVS. "We get to bring cutting edge treatment options to populations who are kind of our most vulnerable and don’t get access to those."
NeuroNews also highlighted the trial. Read the NeuroNews story.
Featured photo at top of woman wearing the Sparrow Ascent device. Photo/Spark Biomedical.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.